cancer vacines

Oncology

Today on the pharmaphorum podcast, Editor in Chief Jonah Comstock welcomes Hedi Ben Brahim and Eric Quéméneur, CEO and chief science off

News

Regeneron's Pasatru will be the second FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.